Lavomax, pills 125mg, 10pcs

Composition

One tablet contains: active ingredient-tilorone dihydrochloride-125 mg;

excipients:

magnesium hydroxycarbonate (heavy magnesium carbonate),

povidone K 30,

calcium stearate;

shell:

sucrose, povidone K 17, copovidone, magnesium hydroxycarbonate (light magnesium carbonate), titanium dioxide, colloidal silicon dioxide (aerosil A-380), quinoline yellow dye, sunset yellow dye, macrogol-6000, beeswax, liquid paraffin, talc.

Pharmacological action

Low molecular weight synthetic interferon inducer that stimulates the formation of all types of interferons (alpha, beta, gamma and lambda) in the body. The main producers of interferon in response to the introduction of tiloron are intestinal epithelial cells, hepatocytes, T-lymphocytes, neutrophils and granulocytes. After oral use, the maximum production of interferon is determined in the gut — liver — blood sequence after 4-24 hours. Tiloron has an immunomodulatory and antiviral effect. According to experimental studies, after a single oral use of tilorone at a dose equivalent to the maximum daily dose for humans, the maximum concentration in the lung tissue of interferon lambda is determined after 24 hours, interferon alpha – after 48 hours. Induction of interferon lambda in the lung tissue increases the antiviral protection of the respiratory tract in influenza and other respiratory viral infections. In human leukocytes, it induces the synthesis of interferon. It stimulates bone marrow stem cells, increases antibody formation depending on the dose, reduces the degree of immunosuppression, and restores the ratio of T-suppressors and T-helpers. It is effective against various viral infections, including influenza viruses, other acute respiratory viral infections, hepatitis viruses and herpesviruses. The mechanism of antiviral action is associated with the inhibition of translation of virus-specific proteins in infected cells, as a result of which viral reproduction is suppressed. Pharmacokineticsafter oral use, tilorone is rapidly absorbed from the gastrointestinal tract. Bioavailability is 60%. About 80% of tilorone binds to plasma proteins. Tiloron is excreted almost unchanged through the intestines (70%) and through the kidneys (9%). The elimination half-life is 48 hours. Tilorone does not undergo biotransformation and does not accumulate in the body.

Indications

In adults, as part of the complex therapy of such diseases and conditions:

• viral hepatitis A, B, C;
• herpetic infection, CMV infection;
• infectious-allergic and viral encephalomyelitis;
• urogenital and respiratory chlamydia, non-gonococcal urethritis;
• pulmonary tuberculosis (as part of complex therapy);
• influenza and other acute respiratory viral infections in adults (treatment and prevention).

Contraindications

Hypersensitivity to tilorone or other components of the drug. The period of pregnancy and lactation. Children’s age (up to 18 years). Sucrose/isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption (the drug contains sucrose).

Side effects

Possible allergic reactions, dyspeptic phenomena, short-term chills. If any of the side effects listed in the instructions get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

Compatible with antibiotics and traditional treatments for viral and bacterial diseases.

There was no clinically significant interaction of Lavomax with antibiotics, traditional treatment of viral and bacterial diseases, and alcohol.

How to take, course of use and dosage

Inside, after eating.

For the treatment of viral hepatitis A — 0.125 g 2 times on the first day, then 0.125 g every other day. The course dose is 1.25 g (10 tablets).

For the treatment of acute hepatitis B: the first and second days-0.125 g, then-0.125 g every other day; course dose-2 g (16 tablets). With a prolonged course of hepatitis B — 0.125 g 2 times a day on the first day, then-0.125 g every other day. Course dose-2.5 g (20 tablets)

For chronic hepatitis B in the initial phase of treatment (2.5 g-20 tablets): in the first 2 days — 0.25 g, then-0.125 g every other day. Continuation phase – from 1.25 g (10 tablets) to 2.5 g (20 tablets) – 0.125 g per week.

The course dose of Lavomax® is 3.75-5 g (from 30 to 40 tablets of 0.125 g), the duration of therapy is 3.5-6 months, depending on the results of biochemical, immunological, and morphological studies that reflect the degree of activity of the process.

In acute hepatitis C:  on the first and second days — 0.125 g, then-0.125 g every other day. Course dose-2.5 g (20 tablets)

For chronic hepatitis C, in the initial phase of treatment (2.5 g-20 tablets): in the first two days — 0.25 g, then-0.125 g every other day.

Continuation phase (2.5 g-20 tablets) – 0.125 g per week. The course dose of Lavomax® is 5 g (40 tablets of 0.125 g), the duration of therapy is 6 months, depending on the results of biochemical, immunological, and morphological markers of the process activity.

In the treatment of influenza and other acute respiratory viral infections:  in the first two days of the disease — 0.125 g, then-0.125 g every other day. The course dose is 0.75 g (6 tablets of 0.125 g each).

For the prevention of influenza and other acute respiratory viral infections:  0.125 g 1 time a week for 6 weeks. For the course — 6 tablets of 0.125 g.

For the treatment of herpetic, CMV infection:  in the first two days — 0.125 g, then-0.125 g every other day. The course dose is 2.5 g (20 tablets of 0.125 g each).

For urogenital and respiratory chlamydia, non-gonococcal urethritis:  in the first two days — 0.125 g, then-0.125 g every other day. The course dose is 1.25 g (10 tablets of 0.125 g each).

As part of the complex therapy of pulmonary tuberculosis:  the first two days of 0.25 g, then 0.125 g every other day. The course dose is 2.5 g (20 tablets of 0.125 g each).

As part of the complex therapy of infectious-allergic and viral encephalomyelitis, the dose is set individually, the course of treatment is 4 weeks.

Overdose

Cases of Lavomax overdose are unknown.

Special instructions

Influence on the ability to drive motor vehicles and manage mechanisms

The use of the drug does not affect the ability to drive vehicles and engage in other potentially dangerous activities that require increased concentration of attention and speed of psychomotor reactions.

Form of production

Tablets

Storage conditions

Store in a dry place, protected from light, at a temperature not exceeding 25 °C

Shelf life

2 years

Active ingredient

Tiloron

Dosage form

Tablets